Skip to content
DataLookout
Menu

NCT07278479

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Oct 22, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 6 → 9 locations
  2. Minor Study sites: 7 to 8
  3. Minor Study sites: 6 to 7
  4. Notable Eligibility criteria expanded, about 22 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 4 entries
    • Study sites: 5 to 6
    • Secondary endpoints: details revised at 6 of 11 entries
    • Study description revised
  5. Minor Study sites: 3 to 5
    • Start date changed from estimate of Apr 2026 to May 18, 2026
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Jan 2026 to Apr 2026
    • Study sites: 1 to 3
    v3
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 8 more changesShow less
    • Eligibility criteria shortened, about 1 word
    • Study sites: 0 to 1
    • Study completion date: Sep 2030 to Sep 2032
    • Start date: Dec 2025 to Jan 2026
    • Interventions: [203Pb]Pb-DOTAM-MAM279 (Other), [212Pb]Pb-DOTAM-MAM279 (Drug) to [203Pb]Pb-MP0712 (Other), [212Pb]Pb-MP0712 (Drug)
    • Secondary endpoints: details revised at 1 of 11 entries
    • Study description revised
    • Study title expanded, about 1 word
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
Timeframe: until 5 years after last dose
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
Timeframe: until 5 years after last dose
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Timeframe: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Timeframe: Phase 2a only; 12 months

Secondary (11)

To assess maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
To assess the area under the curve (AUC) from time 0 to the time of the last quantifiable concentration of [203Pb]Pb-DOTAM-MAM279
To assess half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
To assess the clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
To assess the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Show 6 moreShow less
To quantitatively predict radiation absorbed doses for therapeutic [212Pb]Pb-DOTAM-MAM279 from [203Pb]Pb-DOTAM-MAM279
To assess incidence and severity of safety events following administration of [203Pb]Pb-DOTAM-MAM279
To evaluate PFS
To evaluate DoR
To evaluate DCR
To evaluate OS

Arms and interventions

[203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279Experimental

Patients will receive \[203Pb\]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by \[212Pb\]Pb-DOTAM-MAM279 for treatment

Drugs: [212Pb]Pb-MP0712

Other: [203Pb]Pb-MP0712

Sites

9 sites in 1 country